Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Concinnity Genetics
Edinburgh, Scotland, United Kingdomconcinnitygenetics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Concinnity Genetics has developed an AI-powered synthetic biology platform that creates novel RNA-based control systems to improve the safety of cell and gene therapies. The company recently raised €3.6 million in seed funding to initiate three new preclinical programs focused on key applications within the cell and gene therapy market. No clinical results have been reported yet as all programs are at an early stage.
- Therapeutic areas
- Other
- Modalities
- RNA-based gene control systemsSynthetic biology platforms for gene therapy safety
- Industry
- Biotech
Beyond the preview
Go deeper on Concinnity Genetics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Concinnity Genetics.